Literature DB >> 2762223

Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.

L Putcha1, N M Cintrón, J Tsui, J M Vanderploeg, W G Kramer.   

Abstract

The pharmacokinetics and bioavailability of scopolamine were evaluated in six healthy male subjects receiving 0.4 mg of the drug by either oral or intravenous administration. Plasma and urine samples were analyzed using a radioreceptor binding assay. After iv administration, scopolamine concentrations in the plasma declined in a biexponential fashion, with a rapid distribution phase and a comparatively slow elimination phase. Mean and SE values for volume of distribution, systemic clearance, and renal clearance were 1.4 +/- 0.3 liters/kg, 65.3 +/- 5.2 liters/hr, and 4.2 +/- 1.4 liters/hr, respectively. Mean peak plasma concentrations were 2909.8 +/- 240.9 pg/ml following iv administration and 528.6 +/- 109.4 pg/ml following oral administration. Elimination half-life of the drug was 4.5 +/- 1.7 hr. Bioavailability of the oral dose was variable among subjects, ranging between 10.7 and 48.2%. The variability in absorption and poor bioavailability of oral scopolamine indicate that this route of administration may not be reliable and effective.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2762223     DOI: 10.1023/a:1015916423156

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  A comparison of plasma levels of hyoscine after oral and transdermal administration.

Authors:  C Muir; R Metcalfe
Journal:  J Pharm Biomed Anal       Date:  1983       Impact factor: 3.935

2.  Pharmacokinetics and clinical effects of scopolamine in caesarean section patients.

Authors:  K K Pihlajamäki; J H Kanto; K M Oksman-Caldentey
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-10

3.  A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine.

Authors:  N M Cintrón; Y M Chen
Journal:  J Pharm Sci       Date:  1987-04       Impact factor: 3.534

4.  Pharmacokinetics of drug permeation through human skin.

Authors:  S K Chandrasekaran; W Bayne; J E Shaw
Journal:  J Pharm Sci       Date:  1978-10       Impact factor: 3.534

5.  Placental transfer and pharmacokinetics of atropine after a single maternal intravenous and intramuscular administration.

Authors:  J Kanto; R Virtanen; E Iisalo; K Mäenpää; P Liukko
Journal:  Acta Anaesthesiol Scand       Date:  1981-04       Impact factor: 2.105

6.  Influence of acid-base balance on efficacy and toxicity of drugs.

Authors:  M D Milne
Journal:  Proc R Soc Med       Date:  1965-11

7.  Plasma atropine concentrations determined by radioimmunoassay after single-dose i.v. and i.m. administration.

Authors:  L Berghem; U Bergman; B Schildt; B Sörbo
Journal:  Br J Anaesth       Date:  1980-06       Impact factor: 9.166

  7 in total
  10 in total

1.  Pharmacological modulation of behavioral and neuronal correlates of repetition priming.

Authors:  C M Thiel; R N Henson; J S Morris; K J Friston; R J Dolan
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.

Authors:  S Ahmed; A P Sileno; J C deMeireles; R Dua; H K Pimplaskar; W J Xia; J Marinaro; E Langenback; F J Matos; L Putcha; V D Romeo; C R Behl
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 3.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 4.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

5.  Cognitive enhancement following acute losartan in normotensive young adults.

Authors:  Rasha Mechaeil; Paul Gard; Anne Jackson; Jennifer Rusted
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

6.  Estradiol treatment in young postmenopausal women with self-reported cognitive complaints: Effects on cholinergic-mediated cognitive performance.

Authors:  Alexander C Conley; Kimberly M Albert; Brenna C McDonald; Andrew J Saykin; Julie A Dumas; Paul A Newhouse
Journal:  Hum Psychopharmacol       Date:  2022-02-24       Impact factor: 2.130

7.  The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors.

Authors:  Martin Lochner; Andrew J Thompson
Journal:  Neuropharmacology       Date:  2016-04-22       Impact factor: 5.250

Review 8.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets.

Authors:  Feng-Qian Li; Cheng Yan; Juan Bi; Wei-Lin Lv; Rui-Rui Ji; Xu Chen; Jia-Can Su; Jin-Hong Hu
Journal:  Int J Nanomedicine       Date:  2011-04-28

10.  Low acetylcholine during early sleep is important for motor memory consolidation.

Authors:  Samsoon Inayat; Mojtaba Nazariahangarkolaee; Surjeet Singh; Bruce L McNaughton; Ian Q Whishaw; Majid H Mohajerani
Journal:  Sleep       Date:  2020-06-15       Impact factor: 6.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.